AELIS FARMA

Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders. Founded in 2013, the company is based in Bordeaux, France, and is focused on developing a new class of drugs known as Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This innovative approach to CB1 receptor modulation is based on a natural brain defense mechanism discovered by Aelis Farma's CEO, Dr. Pier Vincenzo Piazza. CB1-SSi selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity, making them potentially safer and more effective than previous generations of CB1 antagonists.

Aelis Farma is currently developing two first-in-class drug candidates: AEF0117 for the treatment of cannabis use disorder (CUD) and AEF0217 for cognitive disorders, including those associated with Down Syndrome. AEF0117 is currently in a phase 2b study in the United States and has shown positive signs of efficacy in a phase 2a clinical trial. AEF0217 has successfully completed safety and pharmacokinetic trials (phase 1 clinical program) in healthy volunteers and is entering phase 1/2 trials. The company has also identified a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor. Aelis Farma's mission is to transform innovation into reliable therapeutic solutions for diseases with unmet medical needs.

Aelis Farma is a biopharmaceutical company dedicated to developing a new class of drugs, the Signaling Specific Inhibitors of the CB1 receptor (CB1-SSi), to treat brain disorders. Their mission is to combine their scientific breakthrough in CB1-SSi with innovative drug development approaches to provide new, effective, and safe treatments for brain diseases with unmet medical needs.

Aelis Farma cultivates a culture of dedication and innovation, driven by a shared passion for developing groundbreaking treatments for brain disorders. The company fosters a collaborative and supportive environment where team members work closely with scientific partners, demonstrating a commitment to excellence and a shared vision of improving the lives of those affected by neurological conditions.